Jounce Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

Bank of America Merrill Lynch Health Care Conference 2015

CAMBRIDGE, Mass.--()--Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced that Richard Murray, Ph.D., chief executive officer, will present a company overview at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas, Nevada on Tuesday, May 12, 2015 at 12:40 p.m. PDT.

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer through discovering and developing novel cancer immunotherapies with the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Jounce utilizes translational science insights to match the right targets to well defined patient populations in order to achieve a higher probability of success and rapid proof-of-concept. The company is pursuing programs against multiple targets in the T cell checkpoint area, as well as programs beyond T cell checkpoints monotherapies, where current immunotherapies may be less likely to be effective. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with initial funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Contacts

Pure Communications, Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com

Contacts

Pure Communications, Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com